NxStage Medical, Inc. (NASDAQ:NXTM) CEO Jeffrey H. Burbank sold 3,000 shares of the company’s stock in a transaction on Thursday, April 20th. The stock was sold at an average price of $27.28, for a total transaction of $81,840.00. Following the sale, the chief executive officer now directly owns 939,086 shares of the company’s stock, valued at approximately $25,618,266.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NxStage Medical, Inc. (NASDAQ:NXTM) traded down 0.68% on Friday, reaching $27.90. 368,993 shares of the company’s stock traded hands. The stock’s 50-day moving average price is $27.13 and its 200-day moving average price is $26.20. NxStage Medical, Inc. has a 52 week low of $15.30 and a 52 week high of $29.99. The stock’s market capitalization is $1.82 billion.
NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Tuesday, February 28th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.02). NxStage Medical had a negative return on equity of 2.97% and a negative net margin of 1.61%. The company had revenue of $93.01 million for the quarter, compared to analyst estimates of $91.82 million. During the same period in the prior year, the company posted ($0.04) EPS. NxStage Medical’s quarterly revenue was up 3.6% on a year-over-year basis.
NXTM has been the subject of a number of analyst reports. Jefferies Group LLC upped their price objective on shares of NxStage Medical to $38.00 and gave the company a “buy” rating in a report on Monday, February 6th. Zacks Investment Research lowered shares of NxStage Medical from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 5th. Canaccord Genuity set a $31.00 price objective on shares of NxStage Medical and gave the company a “buy” rating in a report on Monday, January 23rd. Finally, Northland Securities reissued a “buy” rating and issued a $35.00 price objective on shares of NxStage Medical in a report on Monday, April 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $29.67.
Several institutional investors have recently made changes to their positions in NXTM. Fortaleza Asset Management Inc. raised its position in shares of NxStage Medical by 2.5% in the fourth quarter. Fortaleza Asset Management Inc. now owns 8,055 shares of the medical device company’s stock worth $211,000 after buying an additional 195 shares during the last quarter. Clinton Group Inc. raised its stake in NxStage Medical by 2.8% in the third quarter. Clinton Group Inc. now owns 40,228 shares of the medical device company’s stock valued at $1,005,000 after buying an additional 1,114 shares in the last quarter. California State Teachers Retirement System raised its stake in NxStage Medical by 1.0% in the third quarter. California State Teachers Retirement System now owns 134,815 shares of the medical device company’s stock valued at $3,369,000 after buying an additional 1,300 shares in the last quarter. Rhumbline Advisers raised its stake in NxStage Medical by 2.0% in the third quarter. Rhumbline Advisers now owns 71,591 shares of the medical device company’s stock valued at $1,789,000 after buying an additional 1,385 shares in the last quarter. Finally, BlackRock Group LTD raised its stake in NxStage Medical by 2.0% in the third quarter. BlackRock Group LTD now owns 75,478 shares of the medical device company’s stock valued at $1,887,000 after buying an additional 1,458 shares in the last quarter. 97.26% of the stock is currently owned by institutional investors.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.